These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9223741)

  • 21. Immunopathogenesis of human immunodeficiency virus.
    Ahsan N; Langhoff E
    Semin Nephrol; 1998 Jul; 18(4):422-35. PubMed ID: 9692354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the Murex HIV Ag/Ab Combination assay when used with dried blood spots.
    Lakshmi V; Sudha T; Bhanurekha M; Dandona L
    Clin Microbiol Infect; 2007 Nov; 13(11):1134-6. PubMed ID: 17725648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic correlates of protection against HIV infection: the ally within.
    Piacentini L; Biasin M; Fenizia C; Clerici M
    J Intern Med; 2009 Jan; 265(1):110-24. PubMed ID: 19093964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women.
    Hirbod T; Broliden K
    J Intern Med; 2007 Jul; 262(1):44-58. PubMed ID: 17598814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.
    Beirnaert E; Nyambi P; Willems B; Heyndrickx L; Colebunders R; Janssens W; van der Groen G
    J Med Virol; 2000 Sep; 62(1):14-24. PubMed ID: 10935983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-function studies of the HIV-1 coreceptors.
    Berson JF; Doms RW
    Semin Immunol; 1998 Jun; 10(3):237-48. PubMed ID: 9653050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. WHO clinical staging of HIV infection and disease, tuberculosis and eligibility for antiretroviral treatment: relationship to CD4 lymphocyte counts.
    Teck R; Ascurra O; Gomani P; Manzi M; Pasulani O; Kusamale J; Salaniponi FM; Humblet P; Nunn P; Scano F; Harries AD; Zachariah R
    Int J Tuberc Lung Dis; 2005 Mar; 9(3):258-62. PubMed ID: 15786887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antigen-specific beta-chemokine production and CD8 T-cell noncytotoxic antiviral activity in HIV-2-infected individuals.
    Ahmed RK; Norrgren H; da Silva Z; Blaxhult A; Fredriksson EL; Biberfeld G; Andersson S; Thorstensson R
    Scand J Immunol; 2005 Jan; 61(1):63-71. PubMed ID: 15644124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: correlation of T cell apoptosis with beta2 microglobulin concentration and disease evolution.
    Michel P; Balde AT; Roussilhon C; Aribot G; Sarthou JL; Gougeon ML
    J Infect Dis; 2000 Jan; 181(1):64-75. PubMed ID: 10608752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-risk status of HIV-1 infection in the very low epidemic country, Mongolia, 2007.
    Davaalkham J; Unenchimeg P; Baigalmaa Ch; Oyunbileg B; Tsuchiya K; Hachiya A; Gatanaga H; Nyamkhuu D; Oka S
    Int J STD AIDS; 2009 Jun; 20(6):391-4. PubMed ID: 19451323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges in the development of an effective HIV vaccine: current approaches and future directions.
    Klein E; Ho RJ
    Clin Ther; 2000 Mar; 22(3):295-314; discussion 265. PubMed ID: 10963285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beta-chemokines and protection from HIV type 1 disease.
    Garzino-Demo A; DeVico AL; Cocchi F; Gallo RC
    AIDS Res Hum Retroviruses; 1998 Jun; 14 Suppl 2():S177-84. PubMed ID: 9672236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection.
    Leligdowicz A; Rowland-Jones S
    Expert Rev Vaccines; 2008 Apr; 7(3):319-31. PubMed ID: 18393602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low CD4 T-cell counts despite low levels of circulating HIV: insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease.
    Albuquerque AS; Foxall RB; Cortesão CS; Soares RS; Doroana M; Ribeiro A; Lucas M; Antunes F; Victorino RM; Sousa AE
    Clin Immunol; 2007 Oct; 125(1):67-75. PubMed ID: 17692571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density.
    Willey S; Peters PJ; Sullivan WM; Dorr P; Perros M; Clapham PR
    Antiviral Res; 2005 Nov; 68(2):96-108. PubMed ID: 16157392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bloodborne infections among student voluntary blood donors in Mansoura University, Egypt.
    El-Gilany AH; El-Fedawy S
    East Mediterr Health J; 2006 Nov; 12(6):742-8. PubMed ID: 17333818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune responses that correlate with HIV-1 protection?
    Moog C
    AIDS; 2008 Jul; 22(12):1461-2. PubMed ID: 18614869
    [No Abstract]   [Full Text] [Related]  

  • 38. Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development.
    Betts MR; Gray CM; Cox JH; Ferrari G
    Expert Rev Vaccines; 2006 Aug; 5(4):505-16. PubMed ID: 16989631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Encouraging vaccine results from primate models of HIV type 1 infection.
    Schultz A
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S261-3. PubMed ID: 9814953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can one type of HIV protect against another type?
    Cohen J
    Science; 1995 Jun; 268(5217):1566. PubMed ID: 7777855
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.